Introduction: Dopamine transporter imaging includes SPECT with the radiopharmaceutical 123I-ioflupane, also known as DaTscan. It is most often used to differentiate Parkinson's disease and atypical parkinsonism from essential tremor and secondary parkinsonism. Aim: To analyze the contribution of DaTscan in the diagnosis of parkinsonism in patients referred to this examination to the Department of Nuclear Medicine in the Clinical Hospital Center Rijeka from October 2022 to October 2023. Subjects and methods: 118 subjects participated in the study, and the following data were analyzed: sex, age, referral diagnosis, imaging results, frequency of rigors, tremors and bradykinesia, matching of the patients' clinical picture with DaTscan findings, and levodopa therapy. Data was processed with descriptive statistical analysis in the Microsoft® Excel® 2013. Results: 52 (44%) patients were female and 66 (56%) were male. The average age of the subjects was 69 ± 10 years. In the analyzed period, there were 56 (47%) positive, 48 (41%) negative and 14 (12%) uncertain findings. Patients with a referral diagnosis of Parkinson's disease were positive in 66% of cases (19 out of 29 patients), while 62% of patients (21 out of 34) with a referral diagnosis of tremor had a negative test result. The largest number of patients had all three main symptoms, and the highest proportion of positive findings (39 patients, 72%) was among them. Conclusion: The results of this study are largely consistent with the results of existing studies and show that this test should be indicated in the case of an unclear clinical picture (especially in the early stages of the disease), an insufficient number of symptoms or a lack of response to levodopa therapy.